Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darleukin + Rituximab in Relapsed/Refractory DLBCL
NCT02957019Phase 2Terminated
- Sponsor
- Philogen
- Start
- Jul 2013
- Primary completion
- Sep 2023
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darleukin in diffuse large B-cell lymphoma (DLBCL), sponsored by Philogen. Primary endpoints: Dose Limiting Toxicities and Complete Response Rate. Started Jul 2013; status: terminated.
02
Drugs
darleukin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02957019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957019.